Hardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
DJ Hardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
Hardman & Co Research
Hardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
26-May-2021 / 10:35 GMT/BST
=
Hardman & Co Research: Accrufer launch on schedule
Shield Therapeutics (Shield) is a commercial-stage pharmaceutical company delivering specialty products that address
patients unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru(R)/Accrufer(R) has been
approved by the regulators in both Europe and the US. Following completion of a capital increase in March 2021 to raise
the necessary funds, momentum has picked up significantly in preparing for the US launch of Accrufer, which is due
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Hardman & Co Research: Oakley Capital Investments (OCI): 2021 Capital Markets day: proof of the pudding
DJ Hardman & Co Research: Oakley Capital Investments (OCI): 2021 Capital Markets day: proof of the pudding
Hardman & Co Research
Hardman & Co Research: Oakley Capital Investments (OCI): 2021 Capital Markets day: proof of the pudding
25-May-2021 / 13:40 GMT/BST
=
Hardman & Co Research: 2021 Capital Markets day: proof of the pudding
OCI hosted its annual Capital Markets (CM) day on 18 May 2021. With presentations from Oakley Capital and investee
companies, as well as Q&A, including the OCI board, it gave a clear view of the prospects of the organisation. We have
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;